Functional analysis of a putative ATM/ATR substrate RFWD3
假定的 ATM/ATR 基板 RFWD3 的功能分析
基本信息
- 批准号:7892934
- 负责人:
- 金额:$ 28.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-08-01 至 2013-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAntibodiesApoptosisAtaxia-Telangiectasia-Mutated protein kinaseBRCA1 geneBindingBiochemicalCell CycleCell Cycle ArrestCell physiologyCellsComplexDNA DamageDNA damage checkpointDefectGenetic TranscriptionGenome StabilityGenotoxic StressHumanIn VitroKnowledgeLigaseMDM2 geneMalignant NeoplasmsMapsMass Spectrum AnalysisMediatingMolecularMutationPathway interactionsPeptide HydrolasesPhosphorylationPhosphorylation SitePlayPolyubiquitinProtein p53ProteinsProteomicsPublic HealthRing Finger DomainRoleSignal PathwaySignal Transduction PathwaySmall Interfering RNASystemTP53 geneTestingTumor Suppressor ProteinsUbiquitinUbiquitinationUp-RegulationWD Repeatcross reactivityin vivomulticatalytic endopeptidase complexnoveloncoprotein p21preventprogramsresponsetherapy developmentubiquitin ligaseubiquitin-protein ligaseubiquitin-specific protease
项目摘要
DESCRIPTION (provided by applicant): The tumor suppressor protein p53 is a key regulator of cell cycle arrest, apoptosis and genomic stability. Mutations of p53 that compromise its function occur in 50% of human cancers. In unstressed cells, p53 is maintained at low levels; this is achieved by the ubiquitin-proteasome system, in which p53 is ubiquitinated by E3 ligases and targeted for degradation. In response to genotoxic stress, p53 needs to be rapidly stabilized to upregulate gene transcription. At least five ubiquitin ligases (E6-AP, HDM2, ARF-BP1, COP1, and PIRH2) and an ubiquitin-specific protease (HAUSP) that opposes the ligases have been identified to mediate ubiquitin- dependent proteasomal degradation of p53. However, how these ligases and protease coordinate to regulate p53 stability, particularly after DNA damage is not clear. DNA damage checkpoints are signal transduction pathways that stop or delay the cell cycle progress in the presence of DNA damage. Two kinases, ATM and ATR, are key upstream regulators of this pathway. In a proteomic screen for novel substrates for our preliminary studies, we found that ring finger and WD repeat domain 3 (RFWD3) protein is a putative ATM/ATR substrate that is required for cell cycle arrest. Furthermore, we found that RFWD3 is required for stabilization of p53 in response to DNA damage. We hypothesize that RFWD3 is a novel E3 ligase that plays an important role in mammalian DNA damage response network in part by serving as a positive regulator of p53 stability. We propose to 1) determine the mechanism by which RFWD3 regulates DNA damage checkpoint; whether this is achieved by modulating p53 ubiquitination and stability; 2) to map the RFWD3 phosphorylation sites and test how its phosphorylation by ATM/ATR regulates its function; 3) to isolate RFWD3-associated complexes in cycling cells and in response to DNA damage and identify their components by mass spectrometry; we aim to find and validate important RFWD3 regulators and its E3 ligase substrates, thus revealing clues for its other cellular functions. PUBLIC HEALTH RELEVENCE: This is a newly identified putative ATM/ATR substrate that, when inactivated by siRNA, causes defects in p53 accumulation and cell cycle arrest. Thus, RFWD3 may play an important role in the mammalian DNA damage response network by serving as a novel E3 ligase that positively regulates p53 stability. Uncovering new positive regulator of p53 and understand its function will potentially advance our knowledge of cancer development and treatment.
描述(申请人提供):肿瘤抑制蛋白p53是细胞周期阻滞、细胞凋亡和基因组稳定性的关键调节因子。50%的人类癌症都发生了损害其功能的p53突变。在非应激细胞中,p53维持在低水平;这是通过泛素-蛋白酶体系统实现的,其中p53被E3连接酶泛素化并靶向降解。在基因毒性应激反应中,p53需要快速稳定以上调基因转录。至少有五种泛素连接酶(E6-AP、HDM2、ARF-BP1、COP1和PIRH2)和一种与这些连接酶相反的泛素特异性蛋白酶(HAUSP)被鉴定为介导泛素依赖的p53蛋白酶体降解。然而,这些连接酶和蛋白酶如何协调调节p53的稳定性,特别是DNA损伤后的稳定性尚不清楚。DNA损伤检查点是一种信号转导通路,在存在DNA损伤的情况下停止或延迟细胞周期进程。两个激酶,ATM和ATR,是这一途径的关键上游调节因子。在我们初步研究的新底物的蛋白质组学筛选中,我们发现无名指和WD重复结构域3 (RFWD3)蛋白是一种假定的ATM/ATR底物,是细胞周期阻滞所必需的。此外,我们发现RFWD3是p53在DNA损伤反应中稳定所必需的。我们假设RFWD3是一种新的E3连接酶,在哺乳动物DNA损伤反应网络中发挥重要作用,部分是作为p53稳定性的正调节因子。我们建议1)确定RFWD3调控DNA损伤检查点的机制;这是否通过调节p53泛素化和稳定性来实现;2)绘制RFWD3磷酸化位点,并测试ATM/ATR对其磷酸化如何调节其功能;3)在循环细胞和DNA损伤响应中分离rfwd3相关复合物,并通过质谱法鉴定其成分;我们的目标是找到并验证重要的RFWD3调节因子及其E3连接酶底物,从而揭示其其他细胞功能的线索。公共卫生相关性:这是一种新发现的假定的ATM/ATR底物,当被siRNA灭活时,会导致p53积累缺陷和细胞周期停滞。因此,RFWD3可能在哺乳动物DNA损伤反应网络中发挥重要作用,作为一种新的E3连接酶,积极调节p53的稳定性。发现p53新的正调节因子并了解其功能将有可能促进我们对癌症发展和治疗的认识。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YI WANG其他文献
YI WANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YI WANG', 18)}}的其他基金
Functional analysis of a putative ATM/ATR substrate RFWD3
假定的 ATM/ATR 基板 RFWD3 的功能分析
- 批准号:
7893391 - 财政年份:2009
- 资助金额:
$ 28.87万 - 项目类别:
Functional analysis of a putative ATM/ATR substrate RFWD3
假定的 ATM/ATR 基板 RFWD3 的功能分析
- 批准号:
7460173 - 财政年份:2008
- 资助金额:
$ 28.87万 - 项目类别:
Functional analysis of a putative ATM/ATR substrate RFWD3
假定的 ATM/ATR 基板 RFWD3 的功能分析
- 批准号:
7666860 - 财政年份:2008
- 资助金额:
$ 28.87万 - 项目类别:
Functional analysis of a putative ATM/ATR substrate RFWD3
假定的 ATM/ATR 基板 RFWD3 的功能分析
- 批准号:
8306357 - 财政年份:2008
- 资助金额:
$ 28.87万 - 项目类别:
Functional analysis of a putative ATM/ATR substrate RFWD3
假定的 ATM/ATR 基板 RFWD3 的功能分析
- 批准号:
8136628 - 财政年份:2008
- 资助金额:
$ 28.87万 - 项目类别:
STRUCTURE STUDY OF HUMAN NMT BY XRAY CRYSTALLOGRAPHY
X射线晶体学对人体NMT结构的研究
- 批准号:
6483459 - 财政年份:2001
- 资助金额:
$ 28.87万 - 项目类别:
STRUCTURE STUDY OF HUMAN NMT BY XRAY CRYSTALLOGRAPHY
X射线晶体学对人体NMT结构的研究
- 批准号:
6339283 - 财政年份:2000
- 资助金额:
$ 28.87万 - 项目类别:
STRUCTURE STUDY OF HUMAN NMT BY XRAY CRYSTALLOGRAPHY
X射线晶体学对人体NMT结构的研究
- 批准号:
6315663 - 财政年份:1999
- 资助金额:
$ 28.87万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 28.87万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 28.87万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 28.87万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 28.87万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 28.87万 - 项目类别: